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Summary 
Neonatal exposure to antigen is believed to result in T cell clonal inactivation or deletion. Here 
we report that,  contrary to this notion,  neonatal injection of BALB/c mice with a hen egg 
lysozyme peptide 106-116 in putative "tolerogenic" doses induced a T  cell proliferative and an 
immunoglobulin  G  (IgG)  antibody  (Ab)  response  of both  T  helper  cell  1  (Thl)-  (IgG2a, 
IgG2b, and IgG3) and Th2-dependent (IgG1) isotypes. Upon subsequent challenge with the 
peptide in complete Freund's adjuvant in adult life, although this neonatal regimen suppressed 
proliferation and the production of Thl cytokines (interleukin[IL]-2 and interferon ~/), Th2 cy- 
tokine (IL-5, IL-4, and IL-10) secretion was increased, and the serum levels of Thl- and Th2- 
dependent isotypes of peptide-specific Ab remained elevated. The in vitro proliferative unre- 
sponsiveness in Thl cells could be reversed by Abs to Th2 cytokines (IL-4 and IL-10). Thus, 
neonatal treatment with a peptide antigen induces T  cell priming including production of IgG 
Abs of both Thl- and Th2-dependent isotypes. Upon subsequent peptide exposure, the pep- 
tide-specific T  cell responses undergo an effective class switch in the direction of Th2, resulting 
in T  cell proliferative unresponsiveness. Accordingly, this shift towards increased Ab produc- 
tion to autoantigen could be deleterious in individuals prone to autoantibody-mediated dis- 
eases. Indeed, neonatal treatment with a self-autoantigenic peptide from an anti-DNA mono- 
clonal Ab (A6H 58-69) significantly increased the IgG anti-double-stranded DNA Ab levels in 
lupus-prone NZB/NZW  F1  mice,  despite  suppressing peptide-specific T  cell proliferation. 
This adverse clinical response is in sharp contrast to the beneficial outcome of neonatal treat- 
ment with autoantigens in Thl-mediated autoimmune diseases, such as autoimmune encepha- 
lomyelitis, as reported by others. A Thl to Th2 immune deviation can explain the discordant 
biological responses after the presumed induction of neonatal tolerance in autoantibody- vs. 
Thl-mediated autoimmune diseases. 
H 
'ow does the immune system evade harmful self reac- 
.tivity in early life? This important question relating to 
the establishment of self tolerance has been addressed in ex- 
perimental models of tolerance, where  neonatal injection 
of proteins  or their peptide  determinants  has  resulted in 
Ag-specific  unresponsiveness  in  the  adult  animal  (1-10). 
This  approach  of inducing neonatal  tolerance to  autoAg 
has been used in attempts to block the development of dis- 
ease in experimental models of autoimmunity, such as ex- 
perimental  allergic  encephalomyelitis  (EAE)  1,  collagen- 
induced arthritis (CIA), and diabetes (10-13). 
Neonatally induced T  cell unresponsiveness has been at- 
tributed to several mechanisms,  including  clonal deletion 
and/or anergy of Ag-reactive cells (6-10), or generation of 
specific suppressor or regulatory cells  (2, 4, 5). Most work 
on neonatal tolerance suggesting clonal deletion or inacti- 
vation as its mechanism has been based on the inability to 
mount Ag-specific T  cell responses, either proliferative, or 
proliferative and helper for Ab production, after subsequent 
antigenic  challenge  (1-3,  7-10).  In  contrast  to  these  re- 
ports, we found that mice treated neonatally with a peptide 
underwent a state of"split tolerance," i.e., an increased IgG 
Ab response despite a marked decrease in T  cell prolifera- 
tion (14).  To further understand the consequences of neo- 
1Abbreviations used in this paper: BWFI, New Zealand black/New Zealand 
white F1; CIA, collagen-induced  arthritis; ds, double stranded; EAE, ex- 
perimental allergic encephalomyelitis;  MBP, myelin basic protein; p106, 
hen lysozyme  peptide 106-116; p58~ peptide A6H 58-69; PPD, purified 
protein derivative. 
This paper was presented  in part at the 1993 Clinical Research Meeting, 
Washington, DC (1993. Clin. Res. 41:243A) and at the Experimental  Bi- 
ology 1994 Meeting, Anaheim, CA (1994. FASEB Fed. Am.  Sac, Exp. 
Biol. J. 8:A205). 
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T  cell proliferation, cytokme production (IL-2, IFN-% IL-4, 
IL-5, and IL-10), and in vivo IgG Ab responses in BALB/c 
mice treated neonatally with a hen egg lysozyme peptide 106- 
116 (p106) before and after subsequent peptide challenge. 
CD4 +  T  cells have  been  divided into  Thl,  Th2,  and 
Th0 subsets, depending, on their cytokine secretion profile 
and  their  specific  function  (15).  Thl  cells  secrete  IL-2, 
IFN-% and TNF-~, and Th2 cells secrete IL-4, IL-5, IL-6, 
and IL-10 in response to Ag (15); Th0 cells can secrete mix- 
tures of both types. Thl  ceils help in the Ig isotype switch 
from  IgM to  lgG2a, whereas Th2  cells help in  the switch 
to IgG1 and IgE (16). The two types ofT  cells reciprocally 
regulate  each  other  through  the  cytokines  they  secrete, 
with  IL-4 and  IL-10 inhibiting Thl  cells, and  IFN-y in- 
hibiting Th2  cells (15).  Selective cytokine production and 
the resultant immune response may be protective or patho- 
genic  in  autoimmune  and  other  pathological states  (17). 
For example,  in EAE,  autoAg-specific immune  deviation 
from Thl to Th2 has a profound effect on disease (18-20). 
In  this report,  we  demonstrate that  a  putative neonatal 
"tolerogenic" regimen (8) in itself can prime and activate T 
cell responses, and upon subsequent peptide challenge, in- 
duces immune deviation towards Th2, resulting in prolifer- 
ative  unresponsiveness.  Control  animals  immunized  with 
p106  in  CFA produce  a  predominant  Thl-like  response. 
Although Ag exposure in neonatal life has been suggested 
to result in clonal inactivation, deletion, or suppressor cell 
induction (3-10), our data support "immune deviation" as 
a major mechanism of neonatal tolerance. 
We tested the biological significance of our findings in a 
model  in  which  peptides  derived  from  the  V  region  of 
heavy  chains  of syngeneic autoAb  upregulate  autoimmu- 
nity in the lupus-prone NZB/NZW  F1 (BWF1) mice (21- 
23). We reasoned that the enhanced Ab responses resulting 
from neonatal split "tolerance" to autoAg may be deleterious 
in autoAb-mediated diseases, such as SLE. Indeed, neonatal 
treatment with a self autoAb-derived peptide (A6H  58-69 
[p58])  accelerated  autoAb  production  in  BWF1  mice. 
Thus, while neonatal tolerance to autoAg confers resistance 
to the development of Thl-mediated autoimmune diseases 
such as EAE and CIA (10-13),  it may accelerate disease in 
Ab-mediated autoimmunity,  providing an  applied test for 
our  hypothesis that  "neonatal tolerance"  actually involves 
immune deviation from Thl  to Th2. 
Materials  and Methods 
Animals.  BALB/c and BWF1 mice were bred in the UCLA 
Rheumatology Vivarium (NZB and BALB/c stock were derived 
from mice purchased from Jackson Laboratory [Bar Harbor, ME]; 
NZW stock was derived from mice received from the National 
Institutes of Health  [Bethesda, MD]). Animals were maintained 
in accordance with the guidelines of the UCLA Animal Research 
Commattee. 
Peptides.  Peptides p106 (NAWVAWRNRCK) and p58 (FYN- 
QKFKGKATL) were synthesized in the UCLA Peptide Synthesis 
Facility using F-moc  chemistry. Peptide p106 is an  I-Ea-binding 
dominant determinant in the H-2  a haplotype (24),  and p58 is an 
I-E  a- and I-EU-restricted immunodominant peptide derived from 
the  VH  region of an  anti-DNA mAb  (21,  22).  The  synthetic 
polypeptides were analyzed for purity by high-performance liquid 
chromatography and by mass spectroscopy. The peptides chro- 
matographed essentially as a sharp single peak. The purified pep- 
tides were found to have the expected molecular mass. 
Neonatal Treatment  for the Induction of Tolerance.  Newborn  mice 
received two injections of 20 I~g (14-15 nmol) ofpeptide in 50 ~1 
of emulsion containing IFA (Difco Laboratories, Detroit, MI) i.p. 
at 24 and 72 h  after birth, a regimen previously reported to in- 
duce T  cell tolerance (8).  Control littermates received 50 txl of 
PBS/IFA emulsion using the same time course. 
Immunization.  At 8-12 wk of age, nfice that were peptide- 
treated and PBS-injected mice were immunized subcutaneously 
at the base of their tails and in the hind footpads with 5 ~g (3.5 
nmol)  of peptide  emulsified  1:I  in  CFA  (Difco  Laboratories). 
Mice in each group were bled and killed after 9-10 d, and cells 
from the draining LN and spleen were collected to study prolifer- 
ative responses. Sera were collected, frozen, and later tested for 
IgG Ab to the peptide. Age-matched untreated mice were bled to 
determine the background OD for peptide-reactive Ab. 
T  Ceil Proliferation Assays.  Lymphocyte suspensions were pre- 
pared from the draining LNs and spleen. The LN or splenic cells 
(5  ￿  10  s cells/well) were incubated in 200 p~l of serum-free me- 
dium (HL-1; Ventrex, Portland, ME) with 2 mM r-glutamme in 
96-well microtiter plates without Ag, with different concentra- 
tions of each peptide, or with purified protein derivative (PPD) of 
Mycobacterium tuberculosis (700  U/ml;  Evans  Medical Ltd., Lang- 
hurst, UK) for 5 d. The cells were pulsed with  1 I.~Ci [3H]TdR 
during the last 18 h of the culture. The cells were collected onto 
glass fiber filters with a semiautomatic cell harvester (Skatron In- 
struments, Sterling, VA), and the radioactivity was measured in a 
beta counter (Beckman Instruments, FuUerton,  CA). Positive con- 
trol responses were those to PPD.  Negative controls were cells 
but no Ag (background cpm), or cells cultured with an irrelevant 
peptide. Results are expressed as the mean triplicate Acpm (cpm 
with Ag -  background cpm). 
Determination of Ab to Peptide.  Peptide  (pl06  and  p58)-spe- 
cific Ig levels for  IgG  and  isotypes  ([gG1,  IgG2a,  IgG2b,  and 
IgG3) were determined by ELISA. Peptide (0.3-0.6 txg) was in- 
cubated in 96-well high-binding microtiter plates (Costar Corp., 
Cambridge, MA) overnight at 4~  After washing and blocking 
with 10% FCS in PBS, test sera were added at serial threefold di- 
lutions beginning at  1:30,  and were incubated for  1 h  at 37~ 
After three washes,  alkaline phosphatase-conjugated goat  anti- 
mouse  IgG  or  isotypes  (Fisher Biotech,  Pittsburgh,  PA)  were 
added and incubated at 37~  for 1 h. After washing, the color re- 
action was  developed by adding  1 mg/ml p-nitrophenyl phos- 
phate (Sigma),  and after 30 rain, read at 405  nm using an EL1SA 
reader (M600; Dynatech, Chantilly, VA). Results are expressed as 
the mean +  SEM of mean triplicate AOD (i.e., actual OD -  OD 
in sera of age-matched unmanipulated mice). 
Detection of Lymphokines in Culture Supematants.  Neonatally  treated 
mice were immunized as described in the "Immunization" sec- 
tion above. 9-11  d later, LN and spleen cells were collected and 
cultured separately with medium alone, PPD, or peptide. Culture 
supematants were collected after 24-30 h for IL-2, and after 48- 
60 h for detection oflFN-y, IL-4, IL-5, and IL-10. IL-2 was de- 
tected by a standard bioassay using an IL-2 indicator cell line, a 
subclone of CTLL-2, which does not respond to murine rlL-4 
(25). The proliferative responses of this cell fine could be blocked 
by an anti-murine 1L-2 mAb,  $4B6  (26).  IL-2 standard curves 
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levels were detected by a standard bioassay using an IL-4-depen- 
dent cell hne, CT.4S (27),  kindly provided by Dr. William Paul 
(National Institutes of Health, Bethesda, MD).  Proliferative re- 
sponses of CT.4S  were blocked by an anti-IL-4 mAb,  11B.11 
(28), a kind gift from Dr. Craig Reynolds (National Cancer Insti- 
tute, Frederick, MD). IL-4 was also detected by a capture ELISA 
using mAb pairs purchased from PharMingen.  Standard curves 
were generated using IL-4 that was generously provided by Dr. 
Steven Gillis (Immunex Corp., Seattle, WA). IFN-"/, IL-5, and 
IL-10 levels were determined by a capture ELISA using purified 
mAb  pairs,  and  murine  IFN-',/,  IL-5,  and  IL-10  as  standards 
(PharMingen) (22, 29). 
Measurements of Effect of Neonatal Treatment with p58 in Lupus- 
prone BWF1 Mice.  Neonatal BWF1 mice were treated with p58/ 
IFA in  "tolerogenic" doses described above (8),  or with  PBS/ 
IFA. Both groups of mice were monitored for serum IgG anti- 
p58 and anti-DNA Ab levels and chnical nephritis. Serum Ab to 
DNA were measured by a standard ELISA, as described previ- 
ously (22, 30). Anti-double-stranded (ds) DNA Ab titers are ex- 
pressed as units per millihter, using a positive reference standard 
of pooled serum from 8-mo-old BWF1 mice. Proteinuria was es- 
timated by urine examination using albustix (Ames, Elkhart, IN); 
azotemia was estimated using azostix (Ames) (22). 
Statistical Analysis.  Comparisons between peptide-treated and 
control groups were done using Student's t test and the rank sum 
Mann-Whitney U test. 
Results 
Neonatal Exposure to the Putative "Tolerizing" Peptide Regi- 
men Itself Induced a T  Cell Proliferative and Helper Response. 
6-10-wk-old BALB/c  mice  treated neonatally with  p106 
in  IFA had  a  peptide-specific splenic  T  cell prohferative 
(Fig. 1 A) and an IgG Ab response (Fig. 1 B), even before 
any immunization with the peptide. These peptide-reactive 
Ab were of both Thl  (IgG2a, IgG2b, and IgG3)- and Th2 
(IgG1)-dependent IgG isotypes, IgG1  being predominant 
(Fig. 1,  C  and D, and data not shown).  Splenic T  cell cul- 
ture  supernatants  from  the  tolerized mice  contained  very 
low levels of IL-4 and  IL-5, but  no  detectable IFN-',/by 
ELISA (data not shown).  T  cell proliferation was  detected 
in all "tolerized" animals tested, IgG Ab responses in 8  of 
12 mice, and cytokine responses in 7  of 12 mice. A  similar 
pattern of observations was observed in two experiments. 
Control PBS/IFA-injected mice  (Fig.  1 A-D),  or mice 
treated neonatally with a control peptide, p58 (not shown), 
did not have detectable pl06-reactive Ab or T  cell prolifer- 
ation. Also, the pl06-treated mice did not have a nonspe- 
cific increase in IgG Ab (such as anti-DNA) or T  cell pro- 
liferation to other Ags, such as p58 (data not shown). 
This  suggests  that  the  putative  tolerizing regimen  itself 
initially induces  either Th0  cells or it induces  both  Thl- 
and  Th2-hke  cells capable of mediating production  of all 
IgG isotypes. 
Peptide-specific T Cell Proliferative Unresponsiveness but Primed 
IgG Ab Formation Occurred upon Subsequent Peptide Immuni- 
zation.  Animals treated with  the peptide-tolerizing regi- 
men showed a marked reduction of peptide-specific T  cell 
proliferation in draining LN cells (Fig. 2 A). T  cell prolifer- 
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Figure  1.  Neonatal peptide administration in a putative  tolerogenic 
regimen (8) induces T cell proliferative and helper responses even before 
any immunogenic challenge. 19 BALB/c neonates received 20 ~g each of 
two injections of p106 in IFA (0--) within 24 and 72 h of  birth. Control 
neonates received PBS in IFA (O---). Both groups of mice were tested 
for splenic T cell proliferation and serum IgG Ab at the age of 6-10 wk. 
(A) Significant (more than threefold) peptide-specific T cell prohferation 
was present in all seven pl06-treated mice tested, but not in controls 
(P <0.01 to <0.001 at different in vitro peptide concentrations, Student's 
t test). The mean +  SEM of mean triplicate Acpm values at different in 
vitro peptide concentrations are shown. Neither group of mice made a 
prohferative response to an irrelevant peptide, p58 (Irr. Pep.). Background 
cpm values in the p106- and PBS-treated groups were 3,300 +  410 and 
3,099 +  1,878, respectively. (B) 12 pl06-treated and 6 control mice were 
tested for the presence of serum IgG anti-p106 Ab. Data shown here are 
the mean + SEM ofOD absorbance values at serial serum dilutions. Pep- 
tide-reactive IgG Ab titers were significantly increased in pl06-treated 
mice (P <0.01 to <0.001,  Mann-Whimey  U test). (C and D) The IgG 
Ab formed in peptide-treated  mice were of both IgG1 and IgG2a iso- 
types (P <0.05 to <0.001, Mann-Whitney  U test). Results are from one 
of two similar experiments. 
ative responses to in vitro PPD stimulation were equivalent 
in peptide-treated vs. PBS-injected animals, demonstrating 
the specificity of unresponsiveness (Fig. 2 A). Peptide-spe- 
cific proliferation was  also decreased in the spleen cells of 
peptide-treated animals (Fig. 2  B), although this effect was 
less pronounced in splenic T  cells than in draining LN cells. 
The decrease in splenic cell prohferation was only 2-3-fold 
(P =  borderline, 0.05)  compared to a  15-50-fold decrease 
in LN cell proliferation (P <0.01 to <0.05, Student's t test). 
Residual proliferative responses in splenic cells from treated 
animals were inhibitable by anti-CD4 or anti-I-E  a Ab (data 
not shown),  suggesting that a significant number  of pl06- 
specific, I-Ea-restricted CD4 +  T  cells had migrated to the 
spleen and/or had escaped the proliferative tolerance pro- 
cess in pl06-tolerized mice. 
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Figure  2.  Upon subsequent exposure to the same 
peptide in CFA in adult life, neonatally  tolerized mice 
develop T cell proliferative  um~ponsiveness,  but prim- 
mg for lgG Ab. Newborn mice received either PBS/ 
IFA (O---) or pl06/IFA (0"-), and were then immu- 
nized with pl06/CFA  at the age of 8-12 wk. 9--10 d 
later, these mice were bled for detection of serum IgG 
Ab, and LN and spleen  tissues were harvested. (A) Pep- 
fide-specific proliferative unresponsiveness  in draining 
LN cells. LN and spleen cells from five mice in each 
group were cultured separately in the presence of me- 
dium alone, PPD, an irrelevant  pepdde (Irr. Pep.), and 
different concentrations  of p106. Results  shown are the 
mean •  SEM of mean Acpm from triplicate culture 
wells. Background cpm values were 986  •  267 and 
1,686 -  381 in p106 and PBS groups, respectively. (B) Splenic T cell proliferation  was also decreased in pl06-tolerized mice. Background  cpm values 
were 1,853 --+ 476 and 1,389 •  257 in p106 and PBS groups, respectively.  Note that T cell hyporesponsiveness  was much less marked in spleen  cells than 
in LN cells. (C) In contrast to decreased proliferative  responses in A and B above, peptide-reacdve  IgG Ab were increased  in neonatally  treated mice. The 
mean •  SEM AOD values from 10 mice in each group are shown. The mean  AOD values in peptide treated mice were 8-19-fold higher than in the 
control group. Similar  results were obtained in another experiment. 
In contrast to  the reduced proliferative response, toler- 
ized  mice  had  an  increase  in  pl06-specific  IgG  Ab  re- 
sponses compared to PBS-injected animals (Fig. 2  C). The 
increase in IgG Ab to the peptide did not result from non- 
specific hypergammaglobulinemia,  since animals treated with 
p106 did not have IgG Ab to irrelevant Ags (data not shown). 
Similarly, mice  that  were  treated  neonatally and  immu- 
nized subsequently  with another peptide (p58) did not have 
pl06-reactive Ab (data not shown). 
In Vivo IgG Isotype Expression in Peptide-tolerized Mice Sug- 
gests Persistence of Both Th 1- and Th2-dependent Ab.  The  en- 
hanced peptide-reactive IgG Ab could be caused by selec- 
tive priming of one CD4 + T  cell subset, Th2-1ike cells, as 
suggested in adult high dose tolerance models (31-33). We 
measured IgG isotypes ofpeptide-specific Ab in "tolerized" 
mice.  Neonatally treated mice made a  potent response of 
both Thl-dependent (IgG2a, IgG2b, and IgG3) and Th2- 
mediated (IgG1) lgG Ab to p106, lgG1 being predominant 
(Fig. 3, and data not shown). 
This indicated clearly that the T  helper function of both 
Thl and Th2 cells was intact after neonatal administration 
ofpeptides in IFA. 
In  Vitro Lymphokine  Secretion Suggests a Th 1 to  Th2  "Im- 
mune Deviation."  To further understand the differential rote 
of Th subsets in the outcome of neonatal tolerance induc- 
tion, we studied lymphokines released by T  cells in culture 
supematants of draining LN or spleen cells from PBS- and 
peptide-treated animals after peptide immunization  in adult 
life (Fig. 4).  IFN-~/and IL-2 levels were  significantly de- 
creased in peptide-tolerized animals (P <0.05 and borderline, 
respectively, Student's t test)  (Fig. 4, A  and B).  In contrast, 
IL-5 and IL-10 were only detected in culture supernatants 
from such mice, but not from control mice (P <0.01  and 
<0.05, respectively, Student's t test)  (Fig. 4, C and D). IL-4 
levels detected  by ELISA were  only slightly increased in 
treated animals (Fig. 4 E). IL-4 levels detected by a bioassay 
using the CT.4S cell line also showed a similar pattern (data 
not  shown).  Control animals  (PBS  tolerized,  pl06/CFA 
immunized) mounted a predominant Thl response (Fig. 4 
A-E).  Thus, in vitro lymphokine production favored the 
speculation that neonatal treatment deviates the subsequent 
immune response towards Th2. 
In Vitro Manipulation of T Cells with Anti-lL-10 and-IL-4 
Restores T Cell Proliferation in Tolenzed Animals.  To  test  the 
hypothesis that in vitro T  cell proliferative tolerance was at 
least in part a result of induction of Th2 cytokines which 
then  downregulate  Thl  activities,  we  cultured  LN  and 
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Figure 3.  Increased  IgG anti-pl06 Ab in mice neonatally  treated with 
pi06 are of both Thl- and Th2-dependent isotypes. Sera from PBS- 
(O---) or p106 (O--)-treated mice described  in Fig. 2 were tested for IgG 
anti-p106 Ab of different isotypes. Results are expressed as the mean + 
SEM of mean triplicate AODs. IgG2b and lgG3 Ab were also increased  in 
treated mice (not shown). The findings  are from one of two similar  ex- 
periments. 
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Figure 4.  Neonatal treatment with p106 results in an in vitro decrease 
in Thl cytokines but an increase in Th2 cytokines. Draining LN cells 
from PBS-treated (hatched bar) or pl06-treated (solid bar) and subsequendy 
immunized mice (n =  5 in each group), as described in the legend of Fig. 
2 were cultured with medium alone, PPD, and peptide. Culture superna- 
tants were assayed for IFN-  T (A), IL-10 (C), 1L-5 (D), and 1L-4 (E) by 
ELISA. The sensitivity of this assay was 100 pg/ml for IFN-T, 60 pg/ml 
for IL-10, 30 pg/rrd for IL-5, and 50 pg/ml for IL-4 shown by the hori- 
zontal lines crossing the figure completely (  ..... -). (B) For detection of 
IL-2 (U/nil), supematants were cultured with an IL-2-sensitive subclone 
of CTLL-2. The background  cpm value of this cell line cultured with 
medium alone was 78 +  10; and in the presence of titered amounts of a 
murine IL-2 standard, 50 U/ml =  70,714 + 2,766, 10 U/ml =  12,350 --- 
1,494, 2 U/ml =  2,070 -+ 46, 0.4 U/ml =  323 s  47, and 0.08 U/rid = 
115 +  10 U/ml. The sensitivity of this assay was 0.3 U/ml. Ikesults are 
expressed as the mean +  SEM from one of three similar experiments. 
splenic T  cells from immunize& pl06--tolerized mice with the 
peptide  (1-10  tzg/ml)  and varying concentrations (0.005- 
50 ixg/ml) ofanti-IL-4 (11B.11) and/or anti-IL-10 (JES5- 
2A5). Peptide-specific splenic T  cell proliferation in pl06- 
tolerized  mice was  restored  (equivalent to  that  in control 
immunized animals) in the presence of both anti-IL-4 and 
-IL-10, whereas these Ab did not significantly affect prolif- 
erative responses in PBS-treated controls (Fig. 5). Anti--IL-10 
or -IL-4 alone had minimal or no effect. LN T  cell prolif- 
eration was also increased, but to  a  lesser degree  (data not 
shown), suggesting that Thl  precursors may have migrated 
away  from  the  LN.  Thus,  reversal  of T  cell proliferative 
unresponsiveness by Ab to Th2 cytokines suggests that the 
presence oflL-4 and IL-10 may be responsible for prolifer- 
ative Thl  tolerance. 
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Figure  5.  Antibodies to IL-10 and IL-4 can restore T cell-proliferative 
hyporesponsiveness in spleen cells of tolerized  animals. BALB/c mice 
were  treated neonatally with p106 (upper  panel, solid bars) or PBS (lower 
"panel, hatched  bars), and were later immunized  as described in the legend of 
Fig. 2. Spleen cells from four mice in each group were cultured in medium 
alone (-/-), in the presence ofpeptide (+/-), and peptide + anti-IL-4 
and/or anti-lL-10. Results are shown as the mean +  SEM ofT cell pro- 
liferation (cpm). These results are from one of two similar experiments. 
Neonatal  Tolerance  Induaion  with p58  Increases  lgG Anti- 
dsDNA AutoAb in BWF1 Mice.  The outcome of neonatal 
treatment  with  p58  in  BWF1  mice  was  similar  to  that 
achieved with p106 treatment in BALB/c mice. Similar to 
the results shown in Fig.  1 B, serum IgG anti-p58 Ab were 
significantly increased  in  p58-treated  mice  compared  to 
PBS-injected mice before any further challenge immuniza- 
tion (Fig. 6 A). Upon subsequent challenge with p58/CFA 
in adult life, T  cell proliferation was decreased in response 
to the peptide in culture, but peptide-specific IgG Ab were 
increased (data not shown). 
We reported  earlier that immunization of young BWF1 
mice with p58 increases circulating IgG Ab to dsDNA and 
accelerates clinical nephritis (21). We reasoned that ifT cell 
responses of Thl  and Th2 were implicated in such an au- 
toAb-mediated disease,  then neonatal treatment that  leads 
to  split tolerance  to  this peptide  might  accelerate  autoAb 
production and clinical disease.  To test this, we compared 
IgG anti-dsDNA levels in the  sera  of p58-treated  animals 
with  those  in  PBS/IFA-injected  controls.  In  conformity 
with our hypothesis, serum IgG anti-DNA levels were fig- 
nificandy increased among p58-treated  mice  compared  to 
controls  (P  <0.01  to  <0.05,  Student's t  test)  (Fig.  6  /3). 
This increase in anti-DNA Ab was associated with  an in- 
crease  in  proteinuria.  The  mean  _  SEM  proteinuria  in 
p58-treated mice was 873 -  309 mg/dl compared to 101  -+- 
36 mg/dl in control mice (P <0.05; Student's t test). Simi- 
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Figure  6.  Neonatal administration of a self-autoAb-derived peptide, 
p58, increases serum levels oflgG anti-p58 and anti-dsDNA Ab in BWF1 
mice. 10 newborn mice in each group were treated with two injections of 
p58/IFA or PBS/IFA within 72 h of birth. Both groups of mice were 
monitored for serum IgG anti-p58 and anti-dsDNA Ab. (A) Serum p58- 
reactive IgG Ab were significantly  increased in peptide-treated mice com- 
pared to PBS-injected mice (*P <0.01, **P <0.001, Student's t test). Re- 
sults are shown as the mean + SEM of  mean triplicate OD at serial serum 
dilutions in 10-12-wk-old mice. (/3) Serum lgG anti-dsDNA Ab levels are 
expressed as the mean -+ SEM U/rnl at different age groups. BWF1 mice 
treated at birth with p58 had a significant increase in anti-DNA Ab than 
in PBS-injected controls (*P <0.01, **P <0.05; Student's t test). 
lar  results  were  obtained in  a  separate  experiment,  where 
10 p58/IFA-treated mice had significant increases  in anti- 
DNA  Ab  and  proteinuria  compared to  5  control peptide 
(pl06)-treated and 11 unmanipulated mice. 
Discussion 
Ag  Exposure in  Neonatal Life  Can  Prime T  Cells Rather 
Than Completely Eliminate~Inactivate Them.  It  is  generally 
believed that Ag exposure in early life results in clonal dele- 
tion or anergy, thus maintaining self tolerance and prevent- 
ing autoimmunity (1,  3, 6, 8-10).  Contrary to this notion, 
we show that a T  cell determinant peptide administered in 
neonatal life can induce T  cell proliferative and IgG Ab re- 
sponses.  The  neonatally  treated  mice had  circulating  IgG 
Ab of both  Thl-  and  Th2-promoted isotypes.  However, 
weak  T  cell proliferative  response,  predominant  IgG1  Ab 
production,  and detectable  Th2  cytokine secretion would 
suggest a preferential priming of Th2-1ike cells by this pep- 
tide administered to newborns. 
Functional Split  Tolerance: Proliferative Tolerance but Primed 
Helper Responses.  Previous attempts to address the mecha- 
nism of neonatal tolerance have used various protein  (3,  7, 
10)  or peptide  (8,  9)  Ags as tolerogens,  and have reported 
different outcomes at the level of T  cell proliferation or Ab 
formation upon subsequent challenge with the same Ag in 
CFA. For example, neonatal injections of deaggregated hu- 
man  gamma  globulin  resulted  in  the  induction  of unre- 
sponsiveness in B as well as T  proliferative and Th cells (3), 
whereas newborns tolerized with myelin basic protein (MBP) 
developed  complete  nonreactivity  to  MBP  at  the  T  cell 
proliferation  level,  but  made  some  anti-MBP  Ab  (10). 
Most  studies  using  minimal  immunogenic  peptides  have 
reported T  cell proliferative  tolerance  (7-9).  In this study, 
we  have  shown  that  neonatal  mice,  treated  with  peptide 
doses corresponding to milligrams  of a protein Ag such as 
IgG, develop tolerogen-specific proliferative unresponsive- 
ness,  but  priming for a  T  helper  response  producing IgG 
Ab upon subsequent peptide  challenge.  This phenomenon 
of functional  split  tolerance  has  not  been  previously  re- 
ported in a neonatal peptide tolerance model. The discrep- 
ancy between ours and previous reports on tolerance in Ab 
production could be caused by differences in the tolerogen 
used, or by the use of a single determinant in a peptide vs. 
multiple  determinants  in protein Ags. Tolerance induction 
to  a  protein  Ag may  involve  many  T  cell  determinants; 
some determinants may acfvate Thl cells,  others Th2 cells, 
or still  others  regulatory  or suppressor  ceils,  and  the  ulti- 
mate outcome may depend on the patterns of their recipro- 
cal regulation.  Differential sensitivity to in vivo adult high 
dose tolerance induction has been shown at the level of Th 
subsets  (31-33).  Parenteral  administration  of large  quanti- 
ties of Ag in adult mice results in a state of tolerance char- 
acterized by unresponsiveness in Thl- but not in Th2-type 
lymphocytes  (31-33),  although  this  view  has  been  con- 
tested by others (34). 
Immune Deviation as a Mechanism of Neonatal split T  Cell 
Tolerance.  In  our  experiments,  control  animals  immu- 
nized with peptide in CFA elicited a predominant Thl  re- 
sponse,  whereas  animals  neonatally  treated  with  peptide 
and subsequently immunized with peptide/CFA had a pre- 
dominant Th2 response. The sequence of events leading to 
this immune deviation may be visualized as follows: neona- 
tal injection of pl06/IFA initially induces peptide-specific 
Th0 or both Thl and Th2. The in vivo peptide/CFA chal- 
lenge in adult life followed by in vitro restimulation  with 
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enon may be similar to other in vitro and in vivo situations, 
where repeated Ag exposure can divert immune responses 
towards Th2 (35, 36). For example, mice immunized once 
with irradiated Schistosoma mansoni cercariae develop a pre- 
dominantly  Thl  response,  while  repeated  immunization 
with the same parasite causes the response to become pre- 
dominantly Th2 (35). In an in vitro system, Thl-hke T  cell 
clones can be converted into Th2-hke after 3 wk of culture 
(36). Increased IL-10 and IL-4 secreted by Th2 cells in cul- 
ture should lead to decreased development and prohfera- 
tion of peptide-specific Thl-like cells, as well as a decrease 
in Thl  type lymphokines (15, 37). In this sense, neonatal 
peptide-induced tolerance actually would represent an ef- 
fective class switch in the direction of Th2, and is brought 
about by repeated exposure of Th cells to the Ag, as well as 
by inhibition of Thl cells mediated by IL-4 and IL-10. 
In  the  experiments  described here,  decreased peptide- 
specific T  cell prohferation in tolerized mice could be re- 
stored to normal by in vitro inhibition of Th2  cytokines 
(Fig. 5), supporting the idea of immune deviation and inhi- 
bition of Thl function. The reversal of proliferative unre- 
sponsiveness was more pronounced in splenic than in LN 
cells.  This suggests  that some peptide-specific Thl  cells in 
treated mice may have migrated from the LN to the spleen 
and other organs during peptide immunization in adult hfe. 
In the spleen, preferential Th2 activation (turning offThl) 
can be reversed with Abs to Th2 cytokines. 
Thus, immune deviation, as well as partial migration of 
peptide-specific Thl cells from the draining LN sites, may 
each contribute to our findings of neonatal split tolerance. 
Although clonal deletion or anergy of some peptide-specific 
T  cell populations cannot be ruled out in our experiments, 
it does not  appear to be  a  major element in this  model, 
since  unresponsiveness in  Thl  cells  could be reversed to 
the control level in the presence of anti-Th2 cytokines. 
How to  Explain  Increased In  Vivo  Th l-dependent  (lgG2a) 
Isotype Expression, but Decreased In Vitro Th I Lymphokine Se- 
cretion, after Immunization of Neonatally  Treated Mice in Adult 
Life.  The findings described in this paper reveal an addi- 
tional interesting phenomenon: peptide-tolerized mice ac- 
tually make increased levels of peptide-reactive Ab of IgG 
isotypes that are considered to be Thl mediated (16), while 
failing to show another Thl property of Ag-specific prolif- 
eration. We can put forth the following possibilities to ex- 
plain  this  intriguing observation:  (a)  persistence of serum 
IgG2a  Ab  that  was  induced by  neonatal peptide-primed 
Thl or Th0, and was formed before peptide challenge and 
immune  deviation;  (b)  differential effects of tolerance on 
separate Thl effector functions, e.g., engaging the TCR of 
a CD8 + T  cell clone in the absence of costimulatory signals 
can result in decreased proliferation and IL-2 secretion, but 
enhanced cytolytic potential (38); and (c) anergy may be es- 
tablished only in high affinity Thl cells, but the remaining 
low affinity Thl may still display a partial IFN-',/response 
that is responsible for IgG2a Ab production. 
It has been reported that tolerized Thl retain their ability 
to  deliver a  signal  that  stimulates  early B  cell activation 
(39).  The second signal  for activation of resting B  cells in 
our case may be delivered by activated Th2. It is known that 
the ability of Thl  to stimulate B  cell proliferation and/or 
Ab synthesis increases significantly if the B  cells have been 
preactivated or cukured with Th2 lymphokines (40). Thus, 
in our case,  it is possible to imagine that B  cells that have 
been activated before the adult peptide challenge can still 
make IgG2a Ab in the presence of partially tolerized Thl 
and activated Th2. 
Functional Relevance  of Neonatal  "split"  Tolerance in  Au- 
toimmune Diseases: Implications in Pathogenesis and Immune In- 
tervention.  We show here that a functional dichotomy ex- 
ists with apparently selective tolerance induction for Thl 
proliferation, but activation of T  helper function for both 
Thl- as well as Th2-dependent Ab isotypes. This observa- 
tion could be relevant for our understanding of therapeutic 
intervention in autoimmune diseases such as EAE and SLE. 
In EAE, interventions that prevent, suppress,  or deviate au- 
toAg-specific Thl responses have a beneficial influence on 
disease  (18-20).  In SLE, production of autoAb, including 
pathogenic  IgG  anti-DNA,  is  dependent  on  T  cell  help 
(22,  41, 42). IL-10 administration in BWF1 mice acceler- 
ates  autoAb production and disease,  while treatment with 
anti-IL-10  Ab  delays  onset  of disease  (43).  Therefore, a 
shift towards Th2  and autoAb production within  all iso- 
types could be deleterious in individuals prone to autoAb- 
mediated diseases. To address  this, we studied the effect of 
neonatal  treatment  with  a  self-autoAb-derived  peptide 
(p58) on the autoAb production in BWF1 mice. Immuni- 
zation with p58  has  been shown previously to  accelerate 
autoimmunity  in  the  BWF1  mice  (21).  In  the  present 
work, BWF1 mice neonatally treated with this peptide had 
a significant increase in IgG anti-DNA Ab, which was asso- 
ciated with functionally split tolerance: T  cell prohferative 
unresponsiveness concomitant with a primed IgG Ab re- 
sponse. Thus, immunogenic regimens and traditional neo- 
natal tolerogenic regimens both induce peptide-specific Th 
stimulating  the  secretion  of IgG  autoAb  in  this  murine 
model of SLE.  Since p58-reactive T  cells  exist in young 
unprimed BWF1  mice  (23),  the  lack  of tolerance at  the 
helper level to this and similar peptides may be physiologi- 
cally significant in the induction and/or maintenance ofau- 
toimmunity. Such Th presumably have both escaped toler- 
ance and been concomitantly primed by this self peptide 
(22,  23).  Thus,  neonatal treatment with an  autoantigenic 
peptide can accelerate autoimmunity in individuals prone to 
autoAb-mediated diseases.  Nevertheless, we have recently 
shown  that intravenous adult high  dose tolerance to p58 
can suppress  both proliferative and Ab responses, delaying 
development of anti-DNA Ab in BWF1  mice (23),  dem- 
onstrating that differences in  dose  and distribution  of Ag 
and the development of the immune system play an impor- 
tant role in influencing the tolerance induction pathway. 
Thus, neonatal treatment of T  cells with Ags,  as well as 
the subsequent induction of immune deviation and result- 
ant split tolerance upon repeated exposure to self Ag, may be 
1619  Singh  et al. deleterious in individuals that are genetically programmed 
to make responses to autoAg that result in pathogenic au- 
toAb. On the other hand, this behavior may prevent wide- 
spread Thl-mediated autoirmnaunity. Clearly, the many pa- 
rarneters  influencing responsiveness vs.  tolerance  must  be 
taken  into  account  to  avert  the  undesired  consequences 
that can follow the administration of Ag. 
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